Goldman Sachs Upgrades M.D.C. Holdings (MDC) to Buy, Sees 21% Upside
MDC Hot Sheet
Rating Summary:3 Buy, 9 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Goldman Sachs upgraded M.D.C. Holdings (NYSE: MDC) from Neutral to Buy with a price target of $30, suggesting 21% upside.
The firm expects the company to cut SG&A by 10%-15% in 2012 just as orders and sales are beginning to grow. Based on this, the firm expects the 30% valuation discount to peers should shrink.
Goldman also said the net cash position provides a higher level of safety and they also like the 4.1% dividend yield.
For an analyst ratings summary and ratings history on M.D.C. Holdings click here. For more ratings news on M.D.C. Holdings click here.
Shares of M.D.C. Holdings closed at $24.78 yesterday, with a 52 week range of $14.79-$32.30.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
The firm expects the company to cut SG&A by 10%-15% in 2012 just as orders and sales are beginning to grow. Based on this, the firm expects the 30% valuation discount to peers should shrink.
Goldman also said the net cash position provides a higher level of safety and they also like the 4.1% dividend yield.
For an analyst ratings summary and ratings history on M.D.C. Holdings click here. For more ratings news on M.D.C. Holdings click here.
Shares of M.D.C. Holdings closed at $24.78 yesterday, with a 52 week range of $14.79-$32.30.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- UPDATE: Williams Financial Group Upgrades Semtech Corp. (SMTC) to Buy; Check Again...Quarter Was Fairly Strong
- Barclays on U.S. REITs: Best Ideas List: Adding HPP; Removing ARE
- Wells Fargo Upgrades Watson Pharmaceuticals (WPI) to Outperform; Actavis Acquisition Adds Growth Prospects
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesRelated Entities
Goldman Sachs, DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
